| Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. | |
| | |
MedLine Citation:
|
PMID: 22438097 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: In Japan, sorafenib is now the first-line therapy for individuals with advanced hepatocellular carcinoma (HCC), but no other treatment is available for such patients. The aim of this study was to assess the efficacy and safety of combination therapy with systemic continuous intravenous infusion of 5-fluorouracil (5-FU) and subcutaneous peginterferon alfa-2a, which was used before sorafenib was introduced to Japan. METHODS: Two hundred and twenty-three HCC patients, who were not amenable to curative surgery, percutaneous ablation, or transarterial chemoembolization (TACE), and for whom intraarterial chemotherapy was not indicated because of the presence of extrahepatic metastasis or stenosis of the common hepatic artery, received peginterferon alfa-2a (90 μg subcutaneously on days 1, 8, 15, and 22) and 5-FU (500 mg/day intravenously given continuously on days 1-5 and 8-12). We assessed their response to treatment and survival, and treatment safety. RESULTS: The response rate was 9.4 % (including six patients with complete response) and the disease-control rate was 32.7 %. The median time to progression was 2.0 months. The overall median survival time was 6.5 months (Child-Pugh class A: 9.2 months vs. Child-Pugh class B: 2.8 months). In a multivariate analysis, Eastern Cooperative Oncology Group (ECOG) performance status >0, Child-Pugh class B, and the presence of macroscopic vascular invasion were independent predictors of poor prognosis. The major grade 3-4 adverse events were leucopenia (13.9 %) and thrombocytopenia (5.8 %). No treatment-related deaths occurred. CONCLUSIONS: This combination therapy was well tolerated and showed promising efficacy. Further studies are needed to establish the usefulness of this treatment. |
| | |
Authors:
|
Koji Uchino; Shuntaro Obi; Ryosuke Tateishi; Shinpei Sato; Miho Kanda; Takahisa Sato; Toru Arano; Kenichiro Enooku; Eriko Goto; Ryota Masuzaki; Hayato Nakagawa; Yoshinari Asaoka; Yuji Kondo; Noriyo Yamashiki; Tadashi Goto; Shuichiro Shiina; Masao Omata; Haruhiko Yoshida; Kazuhiko Koike |
Related Documents
:
|
22759787 - Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metas... 22610937 - Phase ii trial of temozolomide for leptomeningeal metastases in patients with solid tum... 22634537 - Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemor... 22713587 - Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-c... 22138097 - Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-po... 19476857 - Vascular complications of orthotopic liver transplantation: experience in more than 4,2... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-3-22 |
Journal Detail:
|
Title: Journal of gastroenterology Volume: - ISSN: 1435-5922 ISO Abbreviation: - Publication Date: 2012 Mar |
Date Detail:
|
Created Date: 2012-3-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9430794 Medline TA: J Gastroenterol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,51...
Next Document: Genetic polymorphism of pri-microRNA 325, targeting SLC6A4 3'-UTR, is closely associated with the ri...